Restructuring On The Table For FibroGen After Roxadustat Rejection

 
• By Alaric DeArment
  
Malekidneys-cancer
The FDA issued a complete response letter for FibroGen and AstraZeneca's roxadustat in anemia of chronic kidney disease • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Strategy

More from Business